Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Why early de-risking is redefining the path to IND

Why early de-risking is redefining the path to IND

July 15, 2026Posted inBiotechnology

Lonza explains why early de-risking has become a strategic imperative for biotech teams working to reach IND with confidence.

Post navigation

Previous Post
Understanding Agentic AI in Clinical Development
Next Post
Modular Modeling Drives Smarter mRNA Manufacturing modular-modeling-drives-smarter-mrna-manufacturing

Recent Posts

  • Agios says adios to sickle cell program over lackluster phase 2 data
  • Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’
  • Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets
  • Early Genomic Indicators of Praziquantel Resistance in Schistosoma mansoni
  • Flu Virus Interaction with Host Cell Machinery Mapped Inside Infected Cells

Archives

  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top